This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Hospira Eyeing Bid For Danone Unit in Latest Tax Deal

PARIS (The Deal) -- America's unloved tax regime may be about to deliver another European takeover with reports suggesting that Lake Forest, Ill.-based Hospira (HSP) is working on an offer worth about $5 billion for Danone's medical nutrition business.

A successful bid by Hospira would net one of Danone's fastest growing and most profitable, albeit small, operations and provide a route for the U.S. group to slash its tax burden by reincorporating its operations in Europe, a process known as inversion.

Hospira could join AbbVie (ABBV - Get Report) and Medtronic (MDT - Get Report), which, respectively, agreed to pay $54.7 billion for Ireland's Shire (SHPG - Get Report) and $43 billion for Covidien (COV), also of Ireland, in deals that are at least partly motivated by inversion, which liberates cash earned, and already taxed, overseas from a second round of taxation when it is repatriated to the U.S. The U.S. corporate tax rate is 35% and the highest in the OECD. That compares with 12.5% in Ireland, 21% in the U.K. and 33.33% in France, according to KPMG LLP figures, suggesting that a Gallic domicile wouldn't be an obvious option for Hospira.

The spate of inversion deals has drawn the ire of the Obama administration, which has called on Congress to close the loophole, potentially be enacting retroactive legislation. "We need to stop companies from renouncing their citizenship just to get out of paying their fair share of taxes," President Obama said on Thursday. "You know some people are calling these companies 'corporate deserters'."

Hospira, which makes injectable drugs, has not confirmed its intention to move its tax base, or its interest in the Danone's Medical Nutrition business. It has been in talks with Danone for "several weeks" about a cash and share deal that would value the unit at about $5 billion, the Financial Times reported on Friday, without citing its source.

To qualify for an inversion Hospira would need to have at least 20% of its capital held outside of the U.S. Engineering that through a takeover of the Danone unit, would likely require the business to be spun out of its French parent before Hospira acquires it using a significant amount of its own shares. Hospira, which is listed on the New York Stock Exchange, has a market capitalization of $8.64 billion.

Danone has been rumored to be seeking to sell the medical nutrition unit, which makes food for people on restricted diets due to illness, since the start of the year. It tapped JPMorgan & Co. to sound out potential buyers, according to unconfirmed reports, and had held preliminary discussions with Nestle.

Danone's medical nutrition unit posted 354 million euros of sales in the second quarter, accounting for about 6.5% of Danone's total of 5.4 billion euros. Sales at the unit rose 6.2% from a year earlier, making it Danone's second fastest growing segment, behind water, while its trading operating margin of 17.6% made it the most profitable unit that quarter.

Danone could use cash from the sale to invest in its sluggish fresh dairy products business, which it has been expanding in Africa, or its faster growing baby foods operations. Danone declined to comment. Hospira did not answer an out-of-hours email asking for comment.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
HSP $0.00 0.00%
ABBV $60.96 -0.39%
COV $106.71 -1.26%
MDT $79.00 -0.98%
SHPG $186.23 2.90%


Chart of I:DJI
DOW 17,709.85 -120.91 -0.68%
S&P 500 2,064.99 -10.82 -0.52%
NASDAQ 4,777.2430 -28.0480 -0.58%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs